Investor Presentation

154 Investor presentation First six months of 2022 Novo NordiskⓇ In 2021, more than 5 million people with diabetes were reached with affordability programmes 5 out of 35 million people were reached with access and affordability efforts Million patients A number of focused programmes (as of full year 2021) Access to Insulin Commitment • 3 USD ceiling price for human insulin vial offered to 76 low- and middle-income countries, reaching +1.7m patients in 2021 2.2m patients reached at or below the ceiling price in countries outside the commitment¹ 35 LO 5 30 Patients reached in 2021 J Changing Diabetes® in Children Vulnerability assessments US affordability offerings • Providing care for children living with type 1 diabetes ~33k children reached across 23 countries with goal of reaching 100,000 in 2030 • • Ensure availability of affordable insulin for vulnerable patients Tailored affordability plans reaching +82k patients as of 2021 based on assessments conducted locally in 67 countries Suite of affordability offerings including unbranded biologics, My $99 insulin and more . In 2021, ~1m vulnerable patients reached with insulin 1 The access and affordability programmes are not mutually exclusive, implying that the sum of the reach of each programme cannot be interpreted as the total unique number of people with diabetes reached. More info on Novo Nordisk access and affordability programmes can be found at: Access & affordability (novonordisk.com). Changing Diabetes® in Children is a public-private partnership between the International Society for Paediatric and Adolescent Diabetes, the World Diabetes Foundation, Roche, and Novo Nordisk. Changing DiabetesⓇ in Children numbers are for Q1 2022, while all other numbers are for FY2021. M: Millions; K: thousands

View entire presentation